4/A: Clover Health CEO Conrad Wai Amends SEC Filing, Details RSU Vesting and Future Stock Sale

Clover Health Investments, Corp. CEO Conrad Wai filed an amended Form 4 detailing the vesting of performance-based restricted stock units and a future sale of shares under a pre-arranged trading plan.

Summary

• Conrad Wai, CEO of Counterpart Health (a role within Clover Health Investments, Corp.), filed an amended Form 4 to clarify details regarding his beneficial ownership.
• The amendment reflects the achievement of performance conditions for a restricted stock unit (RSU) grant awarded on October 31, 2023.
• On September 13, 2024, 379,866 Class A Common Stock RSUs were earned, with one-half of these units vesting and settling on that date.
• The remaining one-half of the earned RSUs are scheduled to vest on October 31, 2025, contingent on Mr. Wai's continued employment.
• A future sale of 15,203 shares of Class A Common Stock is planned for July 8, 2025, at a weighted average price of $3.26 per share, executed pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2025.
• Following these transactions through July 10, 2025, Mr. Wai's direct beneficial ownership of Class A Common Stock totals 1,699,767 shares.
• An additional 1,613,498 shares are held indirectly in a trust for the benefit of Mr. Wai's family, where he serves as a co-trustee.

Sentiment

Score: 6

Explanation: The document indicates positive performance achievement leading to RSU vesting, which is a good sign. The stock sale is pre-planned and routine, not necessarily negative. Overall, it's a neutral to slightly positive update regarding executive compensation and ownership.

Positives

• Performance-based restricted stock units were earned, indicating the achievement of vesting conditions related to the company's performance.
• The RSU grant on October 31, 2023, led to the earning of 379,866 Class A Common Stock units, reflecting successful performance metrics.

Negatives

• A future sale of 15,203 shares of Class A Common Stock is scheduled for July 8, 2025, which will reduce the direct beneficial ownership of the CEO.

Future Outlook

The remaining one-half of the earned restricted stock units are scheduled to vest on October 31, 2025, contingent on the Reporting Person's continued employment. A future sale of 15,203 shares is planned for July 8, 2025, under a Rule 10b5-1 trading plan.

Management Comments

• The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025.
• The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Industry Context

This filing is a routine insider transaction disclosure for a healthcare technology company. The vesting of performance-based RSUs is common for executives, and sales under Rule 10b5-1 plans are standard practice for managing personal liquidity while avoiding insider trading concerns. It does not directly reflect broader industry trends but is consistent with executive compensation and financial planning practices across various industries.

Comparison to Industry Standards

• This document details an insider transaction, which is standard practice for executives of publicly traded companies across all industries.
• The use of a Rule 10b5-1 trading plan for stock sales is a common and accepted method for insiders to sell shares while adhering to SEC regulations, demonstrating compliance with best practices for managing insider stock transactions.
• The vesting of performance-based restricted stock units is also a typical component of executive compensation packages in the technology and healthcare sectors, aligning executive incentives with company performance.
• No specific comparable companies or projects are mentioned in the document to allow for a direct comparison of results.

Related Party Transactions

• Shares are held indirectly in a trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.

Stakeholder Impact

• Shareholders: The vesting of performance-based RSUs indicates that performance targets were met, which could be viewed positively. The planned sale of shares by a CEO, even under a 10b5-1 plan, is a routine part of executive compensation and liquidity management.
• Employees: The vesting of RSUs for the CEO might signal positive company performance, potentially boosting morale.

Next Steps

• The remaining one-half of the earned restricted stock units will vest on October 31, 2025, subject to the Reporting Person's continued employment.
• A sale of 15,203 shares of Class A Common Stock is scheduled for July 8, 2025, under a Rule 10b5-1 trading plan.

Key Dates

Keywords

Clover Health Investments, CLOV, SEC Form 4/A, Insider Trading, Restricted Stock Units, RSU, Rule 10b5-1, Stock Sale, Beneficial Ownership, Conrad Wai, Corporate Governance